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Blocking the Raft
Mast-cell (MC)-driven diseases 
involve immunoglobulin E (IgE) 
receptor–dependent activation 
and subsequent degranulation, 
and this function is regulated in 
lipid rafts in the cell membrane. 
To explore new therapeutic 
options, Weller and colleagues 
examined the effects of the 
lipid raft–modulating drug 
miltefosine on IgE-dependent 
MC activation. In vitro, 
miltefosine inhibited anti-
IgE-induced MC activation, 
degranulation, and histamine 
release, and, remarkably, 
topical miltefosine treatment 
inhibited human MC-mediated 
inflammatory processes in vivo 
in the skin of allergy patients. 
Thus, raft-disrupting agents 
offer new therapy potential for 
MC-driven disease.  
See page 496
Psoriasis Associations
Approximately 30% of psoriasis 
vulgaris (PV) patients develop 
the inflammatory joint disease 
psoriatic arthritis (PA). Because 
variants in IL12B and IL23R 
have been associated with 
PV, Hüffmeier and colleagues 
examined 748 PA patients, 
1,114 PV patients, and 937 
control patients to determine 
whether these alleles were also 
associated with PA. Two single-
nucleotide polymorphisms 
in IL12B and one in IL23R 
exhibited an association 
with PA and PV; however, 
following stratification for 
the strong PSORS1 risk allele, 
similar results were obtained. 
Interestingly, the IL12B 
and IL23R variants confer 
susceptibility to psoriasis in 
general but are not specific risk 
factors for arthritis.  
See page 355
Diagnosis by Virus
Patients with xeroderma pig­
ment osum (XP) are extremely 
sensitive to sunlight and exhibit 
an accompanying increased risk 
for skin cancer. These individuals 
have deficiencies or mutations in 
nucleotide excision repair genes 
(designated XPA to XPG). Leite 
and colleagues demonstrated that transduction of recombinant adenovirus carrying DNA 
repair genes successfully identified the complementation group of three XP patients. 
In addition, DNA sequencing of the identified genes revealed at least one previously 
un reported mutation in XPC. The authors suggest that this method can be used in place of 
somatic cell fusion and gene reporter assays currently used to identify complementation 
groups in these patients. See page 502 
Hair Loss to Achieve Hair Growth?
Using a recently developed in vitro human model, 
Bodó and colleagues examined the effects of the top­
ical steroid hormones estradiol (E2) and prednisolone 
(P), which have been employed in central Europe for 
hair loss management, on chemotherapy­induced 
hair follicle (HF) dystrophy and alopecia. E2 and P 
together promoted the dystrophic catagen pathway 
response to chemotherapy­induced HF damage. This 
pathway involves enhanced initial alopecia, followed 
by accelerated regrowth of normally pigmented hair 
shafts. Thus, the results of this pilot study support 
the use of topical E2 with P before and after chemo­
therapy to enhance the degree and velocity of hair loss 
in order to facilitate faster regrowth in chemotherapy 
patients. See page 506
Metabolic Mineralization
Pseudoxanthoma elasticum (PXE) is character­
ized by progressive mineralization of connec­
tive tissues. Although mutations in the ATP­
binding cassette protein ABCC6 are known to 
underlie this disease, the mechanism for the 
mineralization remains unclear. Jiang and col­
leagues grafted muzzle skin containing vibrissae 
from wild­type or Abcc6–/– mice onto the backs 
of reciprocal mice and measured subsequent 
mineralization by histopathology. In agreement 
with the notion that PXE is a metabolic disorder, Abcc6–/– grafts on wild­type recip­
ients failed to develop mineralization, whereas wild­type grafts on Abcc6–/– recipients 
resulted in significant mineralization. These results suggest that regaining physiological 
homeostatic conditions in patients may result in a source of treatment for this currently 
incurable disorder. See page 348
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